Europos Sąjunga - italų - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoma, polmone non a piccole cellule - agenti antineoplastici - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Europos Sąjunga - italų - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - agenti antineoplastici - poteligeo è indicato per il trattamento di pazienti adulti affetti da micosi fungoide (mf) o sindrome di sézary (ss) che hanno ricevuto almeno una precedente terapia sistemica.

Europos Sąjunga - italų - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinoma, cellule squamose - agenti antineoplastici - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Europos Sąjunga - italų - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mieloma multiplo - agenti antineoplastici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Italija - italų - Ministero della Salute

tuebingen scientific medical gmbh - forbici monouso per elettrochirurgia laparoscopica

Italija - italų - Ministero della Salute

tuebingen scientific medical gmbh - dissettori monouso per elettrochirurgia laparoscopica

Italija - italų - Ministero della Salute

tuebingen scientific medical gmbh - pinze monouso per elettrochirurgia laparoscopica

Italija - italų - Ministero della Salute

tuebingen scientific medical gmbh - strumentario monouso mono- e bipolare - altro

Italija - italų - Ministero della Salute

wenzhou lubao optics technology co.,ltd - dispositivi per oftalmologia - altri (lenti a contatto vedi y210309)

Europos Sąjunga - italų - EMA (European Medicines Agency)

molmed spa - trapianto allogeneic t cellule geneticamente modificate con un vettore retrovirale codificante per una forma tronca del recettore del fattore di crescita umano bassa affinità (Δlngfr) e l'herpes simplex sono chinasi della timidina del virus (hsv-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - agenti antineoplastici - zalmoxis è indicato come trattamento aggiuntivo nel trapianto di cellule staminali ematopoietiche (hsct) aploidentico di pazienti adulti con neoplasie ematologiche ad alto rischio.